1 3 December 2013
2 CHMP/PKWP/EMA/423716/2013
3 Committee for Medicinal Products for Human Use (CHMP)

4 Sunitinib Product-Specific Bioequivalence Guidance

5 Draft

Draft Agreed by Pharmacokinetics Working Party	**October 2013**
Adoption by CHMP for release for consultation	21 November 2013
Start of public consultation	3 December 2013
End of consultation (deadline for comments)	3 March 2014

6
7

Comments should be provided using this template. The completed comments form should be sent to PKWPsecretariat@ema.europa.eu.

8

Keywords	***Bioequivalence, generics, sunitinib***

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8416
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union

Sunitinib Product-Specific Bioequivalence Guidance

Disclaimer:

This guidance should not be understood as being legally enforceable and is without prejudice to the need to ensure that the data submitted in support of a marketing authorisation application complies with the appropriate scientific, regulatory and legal requirements.

Requirements for bioequivalence demonstration (PKWP)*

BCS Classification**	**BCS Class:** ☐ **I** ☒ **III** ☐ **Neither of the two** **Background:** Sunitinib malate may be considered a high solubility and a low permeability compound.
BE Study design	**single dose** **cross-over**
	healthy volunteers
	☒ **fasting** ☐ **fed** ☐ **both** ☐ **either fasting or fed**

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8416
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union

	Strength: 50 mg because it is the highest strength **Background:** The bioequivalence study should in general be conducted at the highest strength. However, as this is a drug with linear pharmacokinetics and the drug substance is highly soluble, selection of a lower strength than the highest is also acceptable.
	Number of studies: one single dose study
Analyte	☒ **parent** ☐ **metabolite** ☐ **both**
	☒ **plasma** ☐ **blood** ☐ **urine**
	Enantioselective analytical method: ☐ **yes** ☒ **no**
Bioequivalence assessment	**Main pharmacokinetic variables:** AUC_{0-72h} and C_{max}
	90% confidence interval: 80.00– 125.00

* As drug variability has not been reviewed, this guidance is not applicable to highly variables drugs.

** The BCS classification should be confirmed by the Applicant at time of submission based on available data (solubility experiments, literature, etc.). If a drug substance has been classified as BCS class II or IV, no further solubility investigations are needed.